Healthcare Industry News: exosomes
News Release - November 29, 2017
Aethlon Medical Names Dr. Charles J. Fisher Chairman of the BoardSAN DIEGO, Nov. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD as Chairman of its Board of Directors.
"We are truly appreciative that Chuck has agreed to expand his role within our organization," stated Aethlon founder & CEO Jim Joyce. "His leadership in advancing first-in-class therapies to market will no doubt contribute to our mission to commercialize our Hemopurifier® and other life-saving therapeutic candidates."
The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® a "Breakthrough Device" related to the treatment of life-threatening viruses that are not addressed with approved therapies.
"I am pleased and honored the Board of Directors have elected me Chairman of the Board. My goal is to work with management, and the Board of Directors, to develop a product development strategy, leading to regulatory approval and commercialization as rapidly as possible. In doing so, we will consider and evaluate both organic and strategic growth opportunities. I look forward to working closely with my colleagues to achieve our goals," stated Dr. Fisher.
The Aethlon Board of Directors unanimously nominated Dr. Fisher to be non-Executive Chairman and he will remain an independent director under Nasdaq rules.
Dr. Fisher is a physician scientist with a distinguished career in both academia and industry spanning over 30 years. As an experienced executive and entrepreneur, he brings a successful track record of developing operating strategies that take products to markets, drive sales and build profitable companies. Prior to joining industry, Dr. Fisher served as Head of the Section of Critical Care Medicine at The Cleveland Clinic Foundation.
Dr. Fisher's research in sepsis, inflammation, host defense and endothelial dysfunction led to his recruitment to Eli Lilly & Co., where he led the Xigris (activated Protein C) Global Product Team and successfully registered the first drug approved for the treatment of sepsis. Subsequently, he was recruited to Abbott Laboratories as Divisional Vice President for Global Pharmaceutical Research and Development (GPRD), where, among other accomplishments, he guided the registration of Humira (the first fully humanized anti-TNF mab).
He was Chief Medical Officer and Executive Vice President of Cardiome Pharma Corp. where he led the team that invented, developed, registered vernakalant, a novel, first in class, multi-ion channel drug for atrial fibrillation (Brinavess). He currently serves as Executive Chairman of CytoPherx, Inc., a medical device company with novel IP focused on modulating acute and chronic inflammation.
In addition, Fisher is a multi-tour combat veteran, with extensive leadership experience in special operations. He has served as a member of the Defense Science Research Council and on DARPA panels, including one focused on universal host defense.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® a "Breakthrough Device" related to the treatment of life-threatening viruses that are not addressed with approved therapies.
In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses. Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.
Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). Additional information can be found online at www.AethlonMedical.com and www.exosomesciences.com. You can also connect with us on Twitter, LinkedIn, Facebook and Google+.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Forward-looking statement includes statements relating to the public offering and the satisfaction of closing conditions relating to the public offering, as well as general economic and market factors. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2017, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Source: Aethlon Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.